| NCCN Guidelines® insights: hematopoietic growth factors, version 1.2022: featured updates to the NCCN guidelines EA Griffiths, V Roy, L Alwan, K Bachiashvili, J Baird, R Cool, S Dinner, ... Journal of the National Comprehensive Cancer Network 20 (5), 436-442, 2022 | 35 | 2022 |
| The FOSSIL Study: FLAG or standard 7+ 3 induction therapy in secondary acute myeloid leukemia V Vulaj, AJ Perissinotti, JR Uebel, VR Nachar, GB Scappaticci, A Crouch, ... Leukemia research 70, 91-96, 2018 | 25 | 2018 |
| Genomic and Biochemical Analysis of the Diaminopimelate and Lysine Biosynthesis Pathway in Verrucomicrobium spinosum: Identification and Partial Characterization of L,L-Diaminopimelate … VR Nachar, FC Savka, SE McGroty, KA Donovan, RA North, RCJ Dobson, ... Frontiers in Microbiology 3, 183, 2012 | 17 | 2012 |
| Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma E Hoylman, A Brown, AJ Perissinotti, BL Marini, M Pianko, JC Ye, ... Leukemia & lymphoma 61 (3), 691-698, 2020 | 15 | 2020 |
| How to choose an appropriate anticoagulant for cancer-associated thrombosis JK Schaefer, A Elshoury, VR Nachar, MB Streiff, MY Lim Journal of the National Comprehensive Cancer Network 19 (10), 1203-1210, 2021 | 14 | 2021 |
| Chemotherapy remote care monitoring program: integration of SMS text patient-reported outcomes in the electronic health record and pharmacist intervention for chemotherapy … S Hough, R McDevitt, VR Nachar, S Kraft, A Brown, C Christen, D Frame, ... JCO Oncology Practice 17 (9), e1303-e1310, 2021 | 12 | 2021 |
| Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management MJ Homan, JH Reid, VR Nachar, LL Benitez, AM Brown, S Kraft, S Hough, ... Supportive Care in Cancer 29 (11), 6505-6510, 2021 | 9 | 2021 |
| Clinician report of oral oncolytic symptoms and adherence obtained via a patient-reported outcome measure (PROM) VR Nachar, K Farris, K Beekman, J Griggs, S Hough, E Mackler JCO clinical cancer informatics 3, 1-6, 2019 | 9 | 2019 |
| Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma TJ Phillips, D Bond, R Takiar, K Kump, M Kandarpa, P Boonstra, TL Mayer, ... Blood Advances 7 (16), 4518-4527, 2023 | 8 | 2023 |
| Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG GB Scappaticci, BL Marini, VR Nachar, JR Uebel, V Vulaj, A Crouch, ... Annals of hematology 97, 573-584, 2018 | 7 | 2018 |
| Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases AH Tam, AJ Schepers, A Qin, VR Nachar Annals of Pharmacotherapy 55 (6), 697-704, 2021 | 6 | 2021 |
| Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas TM Weis, BL Marini, VR Nachar, AM Brown, TJ Phillips, J Brown, ... Leukemia & Lymphoma 61 (5), 1126-1132, 2020 | 6 | 2020 |
| Consensus recommendations on the management of toxicity associated with CD3× CD20 bispecific antibody therapy JL Crombie, T Graff, L Falchi, YH Karimi, R Bannerji, L Nastoupil, ... Blood 143 (16), 1565-1575, 2024 | 5 | 2024 |
| Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment VR Nachar, AJ Perissinotti, GB Scappaticci, DL Bixby, BL Marini Leukemia research 63, 56-61, 2017 | 5 | 2017 |
| COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma VR Nachar, AJ Perissinotti, BL Marini, YH Karimi, TJ Phillips Annals of Hematology 102 (9), 2635-2637, 2023 | 4 | 2023 |
| Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective JC Dela-Pena, MA King, J Brown, VR Nachar Journal of Oncology Pharmacy Practice 28 (3), 646-663, 2022 | 3 | 2022 |
| Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin’s lymphoma GT Baek, NJ Mathis, AJ Perissinotti, BL Marini, A Brown, TJ Phillips, ... Leukemia & Lymphoma 62 (13), 3138-3146, 2021 | 3 | 2021 |
| Clinical controversies in the treatment of cancer-associated venous thromboembolism VR Nachar, AJ Schepers Journal of Oncology Pharmacy Practice 27 (4), 939-953, 2021 | 3 | 2021 |
| Risk of opportunistic infections in patients with bendamustine-associated Lymphopenia and the utility of antimicrobial prophylaxis J Krishnan, V Nachar, BL Marini, AJ Perissinotti, TJ Phillips, MS Kaminski, ... Blood 136, 50, 2020 | 3 | 2020 |
| Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma AC Robinson, VR Nachar Journal of Oncology Pharmacy Practice 26 (5), 1248-1253, 2020 | 3 | 2020 |
